Back to News
Market Impact: 0.18
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet
Source: zacks.com
Analyst EstimatesAnalyst InsightsCompany FundamentalsHealthcare & Biotech
CorMedix's consensus analyst price target implies 67.7% upside potential. However, the article cautions that price targets have limited empirical predictive value; a sustained upward trend in earnings-estimate revisions would be a more meaningful near-term positive catalyst for CRMD shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.18
Ticker Sentiment
CRMD0.28
More News
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- PG&E’s CEO says AI is ‘the best thing that could’ve ever happened to the grid’
- Defense giant Saab sees orders triple after Gripen fighter jet deal with Ukraine
- Volvo Cars shares plunge 25% amid China sales slump and fresh job cuts
- Mark Zuckerberg owns 13% of Meta but controls 61% of its votes. California’s wealth tax would bill him on the 13%
- Eni Raises Investor Payouts as High Fuel Prices Boost Cash Flow